Health ❯ Healthcare ❯ Drug Safety

Adverse Reactions

Injection Site Reactions Immune-mediated Reactions Infections Genetic Testing Hypoglycemia Monitoring and Precautions Warnings and Precautions Diarrhea and Hepatotoxicity Treatment Emergent Adverse Events Myelosuppression Upper Respiratory Infections Neurologic Toxicities Hypersensitivity and Toxicity Monitoring Guidelines Clinical Study Results RINVOQ Safety Profile Black Box Warnings Boxed Warnings

3 ARTICLES

5d ago

FDA Approves Pirtobrutinib for Frontline Treatment of CLL and SLL

The decision follows randomized trial results showing a large progression‑free survival gain while regulators flagged important safety warnings and said overall survival data remain immature.

7 ARTICLES

last wk.

FDA Approves Lilly’s Once-Weekly Basal Insulin Onswik for Adults With Type 2 Diabetes

8 ARTICLES

last mo.

FDA Approves Lisraya as First Oral Treatment for Adult Dermatomyositis

3 ARTICLES

4mo ago

FDA Approves Durvalumab Plus BCG for High‑Risk Non‑Muscle Invasive Bladder Cancer

3 ARTICLES

4mo ago

FDA Clears First Biosimilars to Simponi and Simponi Aria: IMMGOLIS and IMMGOLIS INTRI

3 ARTICLES

6mo ago

Autolus Reports Q4 Loss, Reaffirms 2026 Sales Outlook for AUCATZYL, and Starts AUTO8 Trial

3 ARTICLES

7mo ago

FDA Approves Sotyktu for Active Psoriatic Arthritis as First TYK2 Inhibitor

5 ARTICLES

9mo ago

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

5 ARTICLES

10mo ago

FDA Grants Full Approval to Jaypirca for Relapsed CLL/SLL After Covalent BTK Therapy

4 ARTICLES

11mo ago

Phase 3 Trial Finds Tukysa Improves PFS in First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

6 ARTICLES

last yr.

FDA Approves Palsonify, First Once-Daily Oral Treatment for Acromegaly